TetraPhase Pharmaceuticals To Present Research At ICAAC On Its Novel Chemistry Platform’s Ability To Address Antibiotic Resistance
8/21/2014 8:39:53 AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by